Medtronic reported Q1 FY2026 revenue of $8.578 billion, delivering 4.8% organic growth and adjusted EPS of $1.26, with the quarter aligned to the top end of guidance and EPS modestly ahead of the midpoint. The quarterly performance reflects a bifurcated growth mix: a standout acceleration in Cardiac Ablation Solutions (CAS) and Cardiovascular (CV) portfolio activity, offset by slower momentum in certain Neuroscience and Diabetes ramp-up dynamics. Management signaled an explicit path to an accelerated growth trajectory in the back half of FY26, anchored by ongoing CAS deployment (nearly 50% growth in CAS this quarter, with continued ramp in mapping systems and new catheters like Sphere-360), the anticipated Denervation (Symplicity) market expansion in the U.S. post CMS NCD, and the continued cadence of Diabetes innovations (Simplera Sync, Instinct, and the planned MiniMed separation). The company raised FY26 organic revenue growth guidance to ~5% and reiterated an EPS target range of $5.60-$5.66, underpinned by FX tailwinds and efficiency gains. Medtronic is also advancing its strategy with governance enhancements (two new independent directors, Growth and Operating board committees) and an Investor Day planned for mid-calendar year 2026 to outline a refreshed growth framework and long-term targets.